DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1003800
Title:
Neuropilin 2: Novel Biomarker and Therapeutic Target for Aggressive Prostate Cancer
Descriptive Note:
Technical Report,15 Aug 2014,14 Aug 2015
Corporate Author:
University of Massachusetts Worcester United States
Report Date:
2015-09-01
Pagination or Media Count:
11.0
Abstract:
VEGFNRP2 signaling is critical for the function of prostate cancer stem cells and a prime target for therapy. Surprisingly, however, we observed that that CSCs isolated from prostate tumors are resistant to anti-VEGF bevacizumab therapy. To understand this discrepancy, we generated prostate cancer cells that are resistant to bevacizumab and observed that resistant cells exhibit properties of CSCs compared to sensitive cells. Resistance is mediated by VEGFNRP2 signaling, which is not inhibited by bevacizumab, and it involves the induction of PRex1, a Rac GEF, and consequent Rac1-mediated ERK activation. CSCs isolated from the PTENpc-- transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 down-regulation increases the sensitivity of prostate tumors to bevacizumab. Thus, prostate tumors harbor cells with CSC properties that are resistant to inhibitors of VEGFVEGFR signaling. Combining the use of available VEGFVEGFR-targeted therapies with Rac1 inhibition should improve the efficacy of these therapies significantly.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
